Scarica l'app Stockscreener
7.67
0.92%
0.07
Pre-mercato:
7.71
0.04
+0.52%
Precedente Chiudi:
$7.60
Aprire:
$7.52
Volume 24 ore:
231.45K
Relative Volume:
0.65
Capitalizzazione di mercato:
$185.81M
Reddito:
$68.38M
Utile/perdita netta:
$-20.17M
Rapporto P/E:
-8.6775
EPS:
-0.8839
Flusso di cassa netto:
$-14.13M
1 W Prestazione:
+3.23%
1M Prestazione:
+63.89%
6M Prestazione:
+101.84%
1 anno Prestazione:
-22.53%
Intervallo 1D:
$7.38
$7.9622
Intervallo di 1 settimana:
$7.20
$7.9927
Portata 52W:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Nome
Exagen Inc
Settore
Industria
Telefono
(760) 560-1501
Indirizzo
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, NTRA, A, IDXX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
7.67 | 188.47M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
633.71 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.36 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.45 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
155.08 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IDXX
Idexx Laboratories Inc
|
553.44 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-11 | Iniziato | B. Riley Securities | Buy |
| 2025-07-30 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | Iniziato | Craig Hallum | Buy |
| 2022-08-05 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-04-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cowen | Outperform |
| 2019-10-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Exagen Inc Borsa (XGN) Ultime notizie
Exagen (NASDAQ: XGN) grants director options at $4.31 strike - Stock Titan
Exagen (NASDAQ: XGN) grants Paul Kim 37,500 options at $4.31 - Stock Titan
Exagen Q2 2026 slides: record revenue, stock surges 36% By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN - MarketBeat
GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN - MarketBeat
XGN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentEarnings Acceleration Picks - vinanet.vn
Exagen Stock Price Forecast. Should You Buy XGN? - StockInvest.us
XGN Q2 2026 Earnings: Narrower -$0.13 Loss Beats Estimates; Shares Slip 2.66%Retail Earnings Report - Vinanet
Exagen (XGN) Advances 1.96% to $6.77, Holding Above Key SupportTime Weighted Price - vinanet.vn
Exagen at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - AOL.com
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results - webull.com
Agenus: Q2 Earnings Snapshot - aol.com
Exagen Inc. (XGN) Climbs 4.25% to $6.87, Holding Above Key SupportTPO Profile - dars.gov.et
Exagen (XGN) Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 4.25%Negative Surprise Momentum - vinanet.vn
Exzeo: Q2 Earnings Snapshot - AOL.com
Xenon Pharmaceuticals: Q2 Earnings Snapshot - AOL.com
Exagen Q2 2026 Earnings: Record Revenue and Reduced EBITDA Loss - sekbernews.id
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution - Yahoo Finance
XGN Maintains Buy Rating -- Price Target Raised to $10.00 by TD Cowen - GuruFocus
XGN Reiterates by B. Riley Securities -- Price Target Raised to $12 - GuruFocus
Exagen Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-08-05 - Seeking Alpha
XGN Maintained by BTIG -- Price Target Raised to $9.00 - GuruFocus
Insiders At Exagen Sold US$680k Of Stock Potentially Indicating Weakness - Moomoo
B. Riley Adjusts Price Target on Exagen to $12 From $8, Maintains Buy Rating - marketscreener.com
BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Reve - GuruFocus
Exagen: The Path To Profitability Just Became More Credible (NASDAQ:XGN) - Seeking Alpha
Exagen revenue reaches record level in Q2 2026 as test volume and ASP climb, lifts full year outlook - Traders Union
Exagen Inc. Stock 12‑Month Price Target Raised to $8.71, Implies 86% Upside - TradingView
Exagen Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability - Yahoo Finance
Exagen Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20% - Investing.com Nigeria
Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue H - GuruFocus
Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance - Yahoo Finance
Exagen Q2 2026 slides: record revenue, stock surges 30% on results - Investing.com
XGN: Record revenue, improved margins, and raised guidance highlight strong execution and growth - TradingView
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Exagen Q2 2026 slides: record revenue, stock surges 36% - Investing.com
Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results - MarketBeat
Exagen Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Exagen (NASDAQ:XGN) Beats Q2 Estimates and Raises Full-Year Guidance - ChartMill
EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary - TradingView
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
XGN: Q2 2026 revenue rose 15.9% year-over-year, with improved margins and reduced net loss - TradingView
Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M - Stock Titan
Q2 2026 Exagen Inc Earnings Call Transcript - GuruFocus
Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance - Moomoo
Exagen Inc. Reports Second Quarter 2026 Financial Results - The Manila Times
Exagen reports Q2 2026 revenue $19.9M, narrows adjusted EBITDA loss to $0.1M - tradingview.com
Exagen Inc Azioni (XGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.58%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):